Chargement en cours...

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy

The mammalian target of rapamycin (mTOR) has emerged as an important cancer therapeutic target. Several mTOR inhibitors are currently being tested in cancer clinical trials. Both PI3K/Akt and MEK/ERK signaling regulate mTOR axis. However, inhibition of mTOR activates Akt survival signaling, which in...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wang, Xuerong, Hawk, Natalyn, Yue, Ping, Kauh, John, Ramalingam, Suresh S., Fu, Haian, Khuri, Fadlo R., Sun, Shi-Yong
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2762753/
https://ncbi.nlm.nih.gov/pubmed/18981735
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!